# OnCo record libretto-531 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/libretto-531/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "libretto-531", "NCT04211337" ;
  schema:name "LIBRETTO-531"@en ;
  schema:description "Showed that a drug built specifically for the RET mutation beats the older multi-target pills in medullary thyroid cancer, with far fewer side effects."@en ;
  schema:url <https://onco.cc/trials/libretto-531/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04211337>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2309719> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-02-11" ;
  onco:cancers <https://onco.cc/cancers/thyroid/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/libretto-431/> ;
  onco:people <https://onco.cc/people/lori-wirth/> .